JPRN-UMIN000017115
Completed
未知
Inverse Probability of Treatment Weighting Analysis of Upfront Surgery versus Neoadjuvant Chemoradiotherapy followed by Surgery for Pancreatic Adenocarcinoma with Arterial Abutment - NACRT for PDAC abutted with the artery
Department of Gastroenterological Surgery, Nagoya University Graduate School of Medicine0 sites92 target enrollmentApril 13, 2015
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Pancreatic adenocarcinoma (PDAC) which were deemed borderline resectable through preoperative imaging due to abutment of the major artery, including the superior mesenteric artery (SMA) or common hepatic artery (CHA).
- Sponsor
- Department of Gastroenterological Surgery, Nagoya University Graduate School of Medicine
- Enrollment
- 92
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •(1\) Resectable or unresectable pancreatic cancer (NCCN criteria) (2\)Tumors with encasement or stenosis of the arteries, those abutted with the celiac axis, and those only defined as BR diseases because of the superior mesenteric vein/PV factor (3\) Hematologic, renal, hepatic and respiratory dysfunction (4\)Active infections (5\) Severe cardiac disorder, renal disorder, liver disorder, ulcer with bleeding, intestinal tract paralysis, uncontrollable diabetes mellitus (6\) Presence of pleural effusion or ascites requiring drainage (7\)Pregnant females or nursing mothers who can not stop lactation. Patients or partners, who don't attempt to doing contraception during the study period. (8\) Severe mental disorder (9\) Severe drug hypersensitivity (10\) As determined by the principal investigator or the sub\-investigator the subject is not adequate to participate in the trial.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
A Study of Injections of Pegfilgrastim in Healthy, Adult Human Subjects.CTRI/2018/02/011700Intas Pharmaceuticals Ltd
Completed
Phase 1
A comparative pharmacokinetic and pharmacodynamic study of insulin aspart protamine suspension administered as subcutaneous injection in healthy subjects.CTRI/2023/07/055238Mankind Pharma Limited, India36
Active, not recruiting
Phase 1
A research study to compare different doses of a new investigational medicinal product for treatment of certain patients with Duchenne muscular dystrophyDuchenne Muscular DystrophyMedDRA version: 20.0Level: PTClassification code 10013801Term: Duchenne muscular dystrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]EUCTR2018-001762-42-GBSarepta Therapeutics, Inc.122
Active, not recruiting
Phase 1
A research study to compare different doses of a new investigational medicinal product for treatment of certain patients with Duchenne muscular dystrophyDuchenne Muscular DystrophyMedDRA version: 20.0Level: PTClassification code 10013801Term: Duchenne muscular dystrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]EUCTR2018-001762-42-CZSarepta Therapeutics, Inc.154
Active, not recruiting
Phase 1
A research study to compare different doses of a new investigational medicinal product for treatment of certain patients with Duchenne muscular dystrophyDuchenne Muscular DystrophyMedDRA version: 20.0Level: PTClassification code 10013801Term: Duchenne muscular dystrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]EUCTR2018-001762-42-SISarepta Therapeutics, Inc.154